Advicenne reports 2021 sales up 20% to €3.3 million
January 18, 2022
Paris, France, 18 January 2022 – 7:00am (CET) – Advicenne (Euronext: ADVIC), a specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for those suffering from rare renal diseases, announces today sales of €3.3 million in 2021, representing a 20% growth from the previous year (2020: €2.7 million).